Oncogenic activation of KRAS in colorectal cancer cells, depressed the expression of IRF2 with a capacity to depress CXCL3 expression and eventually enhanced expression of CXCL3 which promoted intratumoral migration of PMN–MDSCs expressing CXCR2, a receptor for CXCL3 [135]. This evidence concerns the gene CXCL3 and colorectal cancer.